Inhibikase Therapeutics, Inc. (IKT) › Shareholders' EquityInhibikase Therapeutics, Inc. (IKT) — Shareholders' EquityAnnual figures by fiscal year, from SEC filings.2019: -$4.49M2020: $9.78M2021: $38.42M2022: $21.04M2023: $10.98M2024: $94.87M2025: $172.90M$172.90M2019Shareholders' Equity (USD)2025Fiscal YearShareholders' EquityChange YoY2025$172.90M+82.3%2024$94.87M+764.2%2023$10.98M-47.8%2022$21.04M-45.2%2021$38.42M+292.6%2020$9.78M+317.9%2019-$4.49M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share